Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Naxitamab Shows Promising Results in Phase 2 Trial for High-Risk Neuroblastoma
• Phase 2 trial of naxitamab with GM-CSF achieved 50% overall response rate in patients with relapsed/refractory high-risk neuroblastoma, meeting its primary endpoint.
• The treatment demonstrated strong efficacy with 58% bone compartment response and 74% bone marrow compartment response, showing particular promise for patients with bone involvement.
• Notable one-year survival outcomes include 93% overall survival rate, while some patients previously treated with anti-GD2 antibodies showed response to naxitamab therapy.
Leukine Clinical Trial Explores Novel Alzheimer's Treatment
• A clinical trial is underway to investigate Leukine's potential in reversing memory loss in Alzheimer's patients.
• Research indicates a connection between rheumatoid arthritis, Down syndrome, and Alzheimer's, influencing treatment approaches.
• Existing Alzheimer's drugs slow cognitive decline but have side effects, necessitating careful patient evaluation.
• Lifestyle interventions like exercise and diet may reduce the risk of developing Alzheimer's and mild cognitive impairment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath